Advanced search
Publication Cover
Expert Review of Hematology Volume 9, 2016 - Issue 1
Submit an article Journal homepage
3,388
Views
13
CrossRef citations to date
0
Altmetric
Editorial

Precision medicine for acute myeloid leukemia

Catherine LaiMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
Judith E KarpMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA;Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USAView further author information
&
Christopher S HouriganMyeloid Malignancies Section, Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USACorrespondence[email protected]
View further author information
Pages 1-3 | Published online: 30 Oct 2015

References

  • Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–795.
  • Klauschen F, Andreeff M, Keilholz U, et al. The combinatorial complexity of cancer precision medicine. Oncoscience. 2014;1(7):504–509.
  • Cancer Genome Atlas Research, N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. New Engl J Med. 2013;368(22):2059–2074.
  • Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481(7382):506–510.
  • Cortes JE, Kantarjian H, Foran JM, et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol. 2013;31(29):3681–3687.
  • Grunwald MR, Levis MJ. FLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemia. Semin Hematol. 2015;52(3):193–199.
  • Shih AH, Jiang Y, Meydan C, et al. Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer Cell. 2015;27(4):502–515.
  • Tyner JW, Yang WF, Bankhead A 3rd, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73(1):285–296.
  • Pemovska T, Kontro M, Yadav B, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3(12):1416–1429.
  • Bennett TA, Montesinos P, Moscardo F, et al. Pharmacological profiles of acute myeloid leukemia treatments in patient samples by automated flow cytometry: a bridge to individualized medicine. Clin Lymphoma Myeloma Leuk. 2014;14(4):305–318.
  • Hourigan CS, Karp JE. Personalized therapy for acute myeloid leukemia. Cancer Discov. 2013;3(12):1336–1338.
  • Kon Kim T, Gore SD, Zeidan AM. Epigenetic therapy in acute myeloid leukemia: current and future directions. Semin Hematol. 2015;52(3):172–183.
  • Ghiaur G, Wroblewski M, Loges S. AML and its microenvironment: a molecular conversation. Semin Hematol. 2015;52(3):200–206.
  • Hourigan CS, Karp JE. Minimal residual disease in acute myeloid leukaemia. Nat Rev Clin Oncol. 2013;10(8):460–471.
  • Hourigan CS, McCarthy P, De Lima M. Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014;20(2):154–163.
  • Klco JM, Miller CA, Griffith M, et al. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015;314(8):811–822.
  • Hokland P, Ommen HB, Mule MP, et al. Advancing the minimal residual disease concept in acute myeloid leukemia. Semin Hematol. 2015;52(3):184–192.
  • Marshall G, Blacklock J, Cameron C. STREPTOMYCIN treatment of pulmonary tuberculosis. Br Med J. 1948;2(4582):769–782.
  • Mandrekar SJ, Dahlberg SE, Simon R. Improving clinical trial efficiency: thinking outside the box. Am Soc Clin Oncol Educ Book. 2015;35:e141–e147.
  • Ramos NR, Mo CC, Karp JE, et al. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. J Clin Med. 2015;4(4):665–695.
  • Burnett AK. Treatment of acute myeloid leukemia: are we making progress? ASH Education Program Book. 2012;2012(1):1–6.
  • Estey E. Why is progress in acute myeloid leukemia so slow? Semin Hematol. 2015;52(3):243–248.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.